Stuart Therapeutics, a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced the addition of Lukas Scheibler, PhD as its Chief Science and Technology Officer.
Live from the annual conference of the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), experts will discuss how the new FDA rule on laboratory developed tests will hinder patient care. This rule will place these tests under duplicative FDA oversight, even though laboratory developed tests are already regulated by the Centers for Medicare & Medicaid Services. This will force many labs to stop performing these essential tests, which play a critical role in diagnosing rare disorders, such as inherited genetic conditions in newborns.
Certest Biotec, is a Spanish an innovative and technology-based company founded in 2002 that has always relied on research and development of new products, as well as exploration of new market niches and opportunities, for its growth.
OnsiteGene Inc. launches XDive®, the first 5-minute real-time PCR instrument, achieving 40 thermal cycles with fluorescent imaging in 5 minutes. With FDA EUA for COVID-19, XDive offers efficiency, processing 16 samples and 64 targets per run. OnsiteGene seeks global distributors and collaborators.
bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.
James J. Collins III, Ph.D., Associate Professor of Pharmacology at UT Southwestern Medical Center who leads groundbreaking research into the parasitic disease schistosomiasis, has been named a Howard Hughes Medical Institute (HHMI) Investigator.
New drug that disrupts two cellular targets would make it much harder for bacteria to evolve resistance
In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors resulting in elimination of the provisional diagnostic categories of Hairy Cell Leukemia Variant (HCLv) and B Prolymphocytic Leukemia.
There’s still much to learn about how doxorubicin, a 50-year-old chemotherapy drug, causes its most concerning side effects. While responsible for saving many lives, this treatment sometimes causes cardiac damage that stiffens the heart and puts a subset of patients at risk for future heart failure. To better understand and potentially control such complications, Tufts University School of Medicine and Tufts Graduate School of Biomedical Sciences researchers have isolated the immune cells that become overactive when patients take doxorubicin.
En un estudio publicado en ACS Central Science, los investigadores han identificado una estrategia para diseñar opioides más seguros. Han demostrado que un opioide experimental, que se une a un sitio no convencional del receptor, suprime el dolor en modelos animales con menos efectos secundarios, especialmente los vinculados a sobredosis fatales.
Researchers at Washington University School of Medicine in St. Louis report that psilocybin, the active ingredient in magic mushrooms, destabilizes a critical network of brain areas involved in introspective thinking. The findings provide a neurobiological explanation for the drug’s mind-bending effects.
In a pioneering study, scientists have decoded the genetic blueprint of Saposhnikovia divaricata, a traditional medicinal herb. The research provides a detailed genome sequence, shedding light on the plant’s evolutionary adaptations and the genetic foundations of its therapeutic benefits.
In a study in ACS Central Science, researchers have identified a strategy to design safer opioids. They showed that an experimental opioid, which binds to an unconventional spot in the receptor, suppresses pain in animal models with fewer side effects — most notably those linked to fatal overdoses.
A recent study has developed nanovesicles (NVs) from activated neutrophils, showcasing their ability to perform molecular debridement and accelerate healing in infectious wounds. This novel method significantly enhances treatment effectiveness, particularly for stubborn diabetic wounds, by targeting and neutralizing deep tissue pathogens.
Chula Medicine in collaboration with the Department of Thai Traditional and Alternative Medicine and Gastroenterologists from Thai medical schools proves that Thai curcumin can help treat dyspepsia as effectively as antacids. The research is poised to push Thai curcumin to the global marketplace.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
